Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

 
• By Mandy Jackson
Lung Cancer
AMG 510 had a 50% response rate in early lung cancer data. • Source: Shutterstock

More from ASCO

More from Conferences